Jade Biosciences (JBIO) Citigroup’s Biopharma Back to School Summit 2026 summary

Pipeline overview and strategic focus

• Developing best-in-class therapeutics for autoimmune diseases, with three main assets sourced from a leading protein engineering partner.

• Lead asset JADE101 targets IgA nephropathy, a $20B U.S. market, with strong phase I data showing nearly 70% IgA reduction sustained for 12 weeks.

• JADE101 is in phase II, with data expected in 2027, and phase III to start in the first half of 2027, aiming for rapid market entry.

• JADE201, an anti-BAFF receptor antibody, is in phase I for rheumatoid arthritis, with a focus on half-life extension for improved patient convenience.

• JADE301, targeting interferon beta for dermatomyositis, enters clinic in Q4 this year, with a readout in 2027; aims to improve on current treatments with better efficacy and convenience.

Competitive landscape and differentiation

• JADE101 is positioned as best-in-class due to superior potency and half-life extension compared to competitors, enabling deeper and more sustained IgA reductions.

• Healthy volunteer IgA reductions are highly predictive of patient outcomes, supporting rapid clinical advancement.

• Convenience and ability to achieve low proteinuria levels are key differentiators, aligning with updated clinical guidelines and nephrologist priorities.

• Selective APRIL inhibition is seen as the preferred strategy for eGFR stabilization, with both selective and dual inhibitors showing efficacy.

Commercial opportunity and market development

• U.S. IgA nephropathy market estimated at 170,000 patients, with 60–75% eligible for advanced therapies; pricing supports a large commercial opportunity.

• Market is expanding, with increasing education and adoption among nephrologists, and room for multiple entrants.

• Ongoing launches by other companies are helping to build awareness and demand, setting the stage for future entrants.